Future large-scale RCTs with individual-level data are essential to better understand the role of baseline metabolic status, genetic factors, and concurrent lifestyle modifications in determining the efficacy of SGLT2 inhibitors in reducing hepatic steatosis. This evidence concerns the gene SLC5A2 and Hepatic steatosis.